Hikma Pharmaceuticals PLC (HIK) Wednesday said that the US Food and Drug Administration (FDA) has approved TYZAVAN, a ready-to-infuse formulation of vancomycin.
TYZAVAN is indicated for treating various bacterial infections in adults and children including septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections.
According to IQVIA, sales of vancomycin injection in the U.S. were nearly $200 million in 2024.
the following infections in adult and pediatric patients (1 month and older) for whom appropriate dosing with this formulation can be achieved: (i) septicemia; (ii) infective endocarditis; (iii) skin and skin structure infections; (iv) bone infections; and (v) lower respiratory tract infections.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.